Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Long-Term Debt Repayments (2019 - 2024)

Sutro Biopharma's Long-Term Debt Repayments history spans 5 years, with the latest figure at $4.1 million for Q1 2024.

  • For Q1 2024, Long-Term Debt Repayments rose 30.66% year-over-year to $4.1 million; the TTM value through Dec 2024 reached $4.1 million, down 67.34%, while the annual FY2024 figure was $4.1 million, 67.34% down from the prior year.
  • Long-Term Debt Repayments for Q1 2024 was $4.1 million at Sutro Biopharma, up from $3.1 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $10.0 million in Q1 2020 and bottomed at $3.1 million in Q3 2022.
  • The 4-year median for Long-Term Debt Repayments is $3.1 million (2022), against an average of $4.1 million.
  • The largest annual shift saw Long-Term Debt Repayments surged 1900.0% in 2020 before it changed 0.0% in 2023.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $10.0 million in 2020, then tumbled by 68.75% to $3.1 million in 2022, then changed by 0.0% to $3.1 million in 2023, then skyrocketed by 30.66% to $4.1 million in 2024.
  • Per Business Quant, the three most recent readings for STRO's Long-Term Debt Repayments are $4.1 million (Q1 2024), $3.1 million (Q4 2023), and $3.1 million (Q3 2023).